Who are Dexamethasone + Ondansetron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexamethasone and ondasetron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamethasone-ondansetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Dexamethasone + Ondansetron — Competitive Intelligence Brief

Dexamethasone + Ondansetron (Dexamethasone + Ondansetron) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + 5-HT3 antagonist combination. Area: Oncology; General Surgery; Gastroenterology.

marketed Corticosteroid + 5-HT3 antagonist combination Glucocorticoid receptor; 5-HT3 receptor Oncology; General Surgery; Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone + Ondansetron (Dexamethasone + Ondansetron) — University of Catania. Dexamethasone suppresses inflammation and immune responses via glucocorticoid receptor activation, while ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexamethasone + Ondansetron TARGET	Dexamethasone + Ondansetron	University of Catania	marketed	Corticosteroid + 5-HT3 antagonist combination	Glucocorticoid receptor; 5-HT3 receptor
Dexamethasone and ondasetron	Dexamethasone and ondasetron	Instituto Materno Infantil Prof. Fernando Figueira	phase 3	Corticosteroid + 5-HT3 antagonist combination	Glucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + 5-HT3 antagonist combination class)

Instituto Materno Infantil Prof. Fernando Figueira · 1 drug in this class
University of Catania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone + Ondansetron — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-ondansetron. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab